Kinetics of Perioperative Circulating DNA in Cancer Surgery

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to determine the kinetics of perioperative circulating DNA in three types of cancer. This first step will enable further studies comparing the potential impact of certain techniques or anesthetic products on cancer surgery.

Official Title
-----------------
Kinetics of Perioperative Circulating DNA in Cancer Surgery

Conditions
-----------------
Breast Cancer, Prostate Cancer, Colon Cancer

Intervention / Treatment
-----------------
* Other: Blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient must have given their free and informed consent and signed the consent form The patient must be a member or beneficiary of a health insurance plan The patient is aged between 18-75 Patient must weigh >40kg The patient will receive adjusted carcinological surgery Indication of curative surgery The patient has already undergone tumoral biopsy prior to surgery The patient has stage M0 cancer of either colon (right or left colonic adenocarcinoma), prostate (adenocarcinoma) or breast (infiltrating carcinoma) Exclusion Criteria: The subject is in a period of exclusion determined by a previous study The patient is under safeguard of justice The subject refuses to sign the consent It is impossible to give the subject informed information The patient is pregnant, parturient or breast feeding Chronic alcoholism The patient has received radiotherapy or chemotherapy periopratively Cancer other than colon, breast or prostate The patient has currently or in the past, had a cancerous lesion Neo-adjuvant therapy (immunotherapy, radiotherapy, chemotherapy) Emergency cancer surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| circulating DNA plasma level test<br> | Other: Blood test<br>* plasma concentration of circulating DNA of specific genes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in concentration of total mutant circulating DNA | ng/mL in plasma | Nine timepoints between Day-1 to Day 3 | 
| Change in proportion of mutant circulating DNA | ng/mL in plasma | Nine timepoints between Day-1 to Day 3 | 
| Change in integrity index of circulating DNA for ACTB gene | concentration of long ACTB ctDNA fragments/concentration of short ACTB ctDNA fragments | Nine timepoints between Day-1 to Day 3 | 
| Change in integrity index of circulating DNA for KRAS gene | concentration of long KRAS ctDNA fragments/concentration of short KRAS ctDNA fragments | Nine timepoints between Day-1 to Day 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in plasma concentration of long (  290bp) fragments of ACTB gene | ng/mL in plasma | Nine timepoints between Day-1 to Day 3 | 
| Change in plasma concentration of short (  145bp) fragments of KRAS gene | ng/mL in plasma | Nine timepoints between Day-1 to Day 3 | 
| Change in plasma concentration of long (  300bp) fragments of KRAS gene | ng/mL in plasma | Nine timepoints between Day-1 to Day 3 | 
| Change in plasma concentration of mutant KRAS DNA fragments | ng/mL in plasma | Nine timepoints between Day-1 to Day 3 | 
| Change in plasma concentration of BRAF DNA fragments with V600E mutation | ng/mL in plasma | Nine timepoints between Day-1 to Day 3 |